Form 4: Phio Director Patricia Bradford Acquires 18,500 Shares

Phio Pharmaceuticals Corp. Director Patricia A. Bradford acquired 18,500 shares of common stock through the vesting of restricted stock units.

Summary

• Patricia A. Bradford, a Director of Phio Pharmaceuticals Corp., acquired 18,500 shares of common stock.
• The acquisition occurred on February 5, 2026, at a price of $0 per share.
• These shares represent the vesting of a restricted stock unit grant.
• Following this transaction, Bradford beneficially owns 45,651 shares of Phio Pharmaceuticals Corp. common stock, which includes other unvested restricted stock units.
• The reported number of securities has been adjusted to reflect prior reverse stock splits.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a moderately positive event, as it increases insider ownership, though the shares were acquired via vesting rather than an open market purchase.

Positives

• An insider, Director Patricia A. Bradford, increased her beneficial ownership in the company by 18,500 shares.
• The increase in ownership aligns the director's interests more closely with those of shareholders.

Negatives

• The shares were acquired through the vesting of restricted stock units, not an open market purchase, which typically signals less direct confidence in the immediate stock price compared to a cash purchase.

Industry Context

StockSavvy.ai notes that insider share acquisitions, even through RSU vesting, can be viewed by the market as a positive signal, indicating continued alignment of management interests with shareholder value, particularly in the biotechnology or pharmaceutical sector where long-term development cycles are common.

Related Party Transactions

• Acquisition of 18,500 shares by Director Patricia A. Bradford through the vesting of restricted stock units, representing equity compensation.

Stakeholder Impact

• Shareholders: Increased alignment of a director's interests with shareholders due to higher beneficial ownership.
• Employees: Reflects standard equity compensation practices for directors.

Key Dates

Recommendation

The filing reports a routine insider transaction involving the vesting of restricted stock units for a director. While it increases insider ownership, it does not provide new fundamental information about the company's operations, financial performance, or strategic direction that would warrant a change in investment stance. It's a standard compensation event.

Keywords

Phio Pharmaceuticals, PHIO, Insider Trading, Form 4, Restricted Stock Units, Director Ownership, Equity Compensation, Beneficial Ownership